Advertisement

Stability of Proline-Containing Peptides in Biological Media

  • K. V. ShevchenkoEmail author
  • I. Yu. Nagaev
  • L. A. Andreeva
  • V. P. Shevchenko
  • N. F. Myasoedov
Article
  • 5 Downloads

Abstract—

New data on peptide drugs characterized by their high stability, which is determined by both introduction of Pro-Gly-Pro in various amino acid sequences and also modification of the glyproline fragment have been summarized. The following proline-containing peptides were used: Pro-Gly-Pro-Leu, ACTH(6-9)Pro-Gly-Pro, 5-oxo-Pro-Arg-Pro and 5-oxo-Pro-His-Pro-NH2. Tritiated peptides had the following specific radioactivity: Pro-Gly-Pro-Leu—35 Ci/mmol, ACTH(6-9)Pro-Gly-Pro—26 Ci/mmol, 5-oxo-Pro-Arg-Pro—60 Ci/mmol and 5-oxo-Pro-His-Pro-NH2—75 Ci/mmol. The labeled peptides were used for determination of their content in vivo. The concentration of Pro-Gly-Pro-Leu, ACTH(6-9)Pro-Gly-Pro, 5-oxo-Pro-Arg-Pro and 5-oxo-Pro-His-Pro-NH2 in the blood was found to be about 200 times more than in the brain for intranasal administration, and about 600 times higher in blood than in the brain after intravenous administration. The stability of proline-containing peptides in vitro experiments was determined using different commercially available peptidases (leucine aminopeptidases, dipeptidases, carboxypeptidases B and Y), and using nasal mucus, rat brain microsomal fraction (RBM) and rat blood plasma. During peptidase hydrolysis of Pro-Gly-Pro-Leu, the main metabolites were Gly-Pro-Leu, Pro-Gly-Pro, Gly-Pro, and Pro-Gly. In the case of peptidase hydrolysis of ACTH(6-9)Pro-Gly-Pro, the main metabolites were Phe-Arg-Trp-Pro-Gly-Pro and Trp-Pro-Gly-Pro. Peptidase hydrolysis of 5-oxo-Pro-His-Pro-NH2, resulted in formation of 5-oxo-Pro-His-Pro as the major metabolite. It was shown that with different methods of peptides administration the composition of the metabolites formed was different. Based on the data obtained, resistance to enzymatic cleavage of peptides and their metabolic pathways were evaluated. Thus, these new data have shown that the above approaches can be used to prolong the action of glyprolines in living organisms. Degradation of proline-containing peptides occurs mainly via degradation of amino acid constituents rather than peptidase action. In general, the data presented in the review indicate the prospect for the use of intranasal route for administration of biologically active peptides for their delivery into the brain.

Keywords:

peptides proteolysis ways of peptide administration tritiated analogs distribution in organs 

Notes

FUNDING

The work was financially supported by the Program of the Basic Research of the Presidium of the Russian Academy of Sciences “Basic Research for the Development of Biomedical Technologies.”

COMPLIANCE WITH ETHICAL STANDARDS

Conflict of interests. The authors declare that they have no conflict of interest.

REFERENCES

  1. 1.
    Ashmarin, I.P., Koroleva, S.V., and Myasoedov, N.F., Eksper. Klin. Farmakol., 2006, vol. 69, no. 5, pp. 3–6.Google Scholar
  2. 2.
    Ashmarin, I.P., Samonina, G.E., Lyapina, L.A., Kamenskii, A.A., Levitskaya, N.G., Grivennikov, I.A., Dolotov, O.V., Andreeva, L.A., and Myasoedov, N.F., Pathophysiology, 2005, vol. 11, no. 4, pp. 179–185.CrossRefGoogle Scholar
  3. 3.
    Bartfai, T., Langl, U., and Hokfelt, T., Neuropept, 1994, vol. 26, pp. 21–28.CrossRefGoogle Scholar
  4. 4.
    Foran, S.E., Carr, D.B., Lipkowski, A.W., Maszczynska, I., Marchand, J.E., Misicka, A., Beinborn, M., Kopin, A.S., and Kream, R.M., Proc. Natl. Acad. Sci. USA, 2000, vol. 97, no. 13, pp. 7621–7626.CrossRefGoogle Scholar
  5. 5.
    Kozlovskaya, M.M., Kozlovskii, I.I., Val’dman, E.A., and Seredenin, S.B., Neurosci. Behav. Physiol., 2003, vol. 33, no. 9, pp. 853–860.CrossRefGoogle Scholar
  6. 6.
    Ashmarin, I.P., Alfeeva, L.Yu., Andreeva, L.A., Grivennikov, I.A., Dubynin, V.A., Kamenskii, A.A., Kozlovskaya, M.M., Levitskaya, N.G., Myasoedov, N.F., Nezavibat’ko, V.N., and Seredenin, S.B., Rus. Patent no. 2206573 (20.06.2003), Byull. Izobret., 2003, no. 17.Google Scholar
  7. 7.
    Alfeeva, L.Yu., Andreeva, L.A., Voronina, T.A., Guzevatykh, L.S., Emel’yanova, T.G., Myasoedov, N.F., and Seredenin, S.B., Rus. Patent no. 2286169 (27.10.2006), Byull. Izobret., 2006, no. 30.Google Scholar
  8. 8.
    Andreeva, L.A., Myasoedov, N.F., Kost, N.V., Meshavkin, V.K., Voronina, T.A., Garibova, T.L., and Seredenin, S.B., Rus. Patent no. 2411248 (10.02.2011), Byull. Izobret., 2011, no. 4.Google Scholar
  9. 9.
    Andreeva, L.A., Mezentseva, M.V., Shapoval, I.M., Shcherbenko, V.E., Ershov, F.I., and Myasoedov, N.F., Rus. Patent no. 2411249 (10.02.2011), Byull. Izobret., 2011, no. 4.Google Scholar
  10. 10.
    Kolomin, T., Shadrina, M., Slominsky, P., Limborska, S., and Myasoedov, N., Neuroscience Medicine, 2013, vol. 4, no. 4, pp. 223–252.CrossRefGoogle Scholar
  11. 11.
    V’yunova, T.V., Andreeva, L.A., Shevchenko, K.V., Shevchenko, V.P., and Myasoedov, N.F., Neurochem. J., 2016, vol. 33, no. 3, pp. 230–237.Google Scholar
  12. 12.
    Shevchenko, K.V., Andreeva, L.A., Nagaev, I.Yu., and Shevchenko, V.P., 6-ya Mezhdunarodnaya konferentsiyaBiologicheskiye osnovy individual’noy chuvstvitel’nosti k psikhotropnym sredstvam” (6th International Conference “Biological Foundations of Individual Sensitivity to Psychotropic Drugs”), Health complex “Klyazma,” Mytishchi district, Moscow region, November 9–13, 2015, p. 64.Google Scholar
  13. 13.
    Ponomareva-Stepnaya, MA, Bakharev, V.D., Nezavibat’ko, V.N., Andreeva, L.A., Alfeeva, L.Yu., and Potaman, V.N., Khim.-Farm. Zhurn., 1986, no. 6, pp. 667–670.Google Scholar
  14. 14.
    Ponomareva-Stepnaya, M.A., Nezavibat’ko, V.N., Antonova, L.V., Andreeva, L.A., Alfeeva, L.Yu., Potaman, V.N., Kamenskii, A.A., and Ashmarin, I.P., Khim.-Farm. Zhurn., 1984, no. 7, pp. 790–795.Google Scholar
  15. 15.
    Ashmarin, I.P., Nezavibat’ko, V.N., Myasoedov, N.F., Kamenskii, A.A., Grivennikov, I.A., Ponomareva-Stepnaya, M.A., Andreeva, L.A., Kaplan, A.Ya., Koshelev, V.B., and Ryasina, T.V., Pavlov Zhurn. Vyssh. Nervn. Deyat., 1997, vol. 47, no. 2, pp. 420–430.Google Scholar
  16. 16.
    V’yunova, T.V., Andreeva, L.A., Shevchenko, K.V., and Myasoedov, N.F., V S’yezd Farmakologov RossiiNauchnyie osnovy poiska i sozdaniya novykh lekarstv” (V Congress of Pharmacologists of Russia “Scientific Basis for the Search and Creation of New Drugs”), Yaroslavl, May 14–18, 2018, p. 48.Google Scholar
  17. 17.
    Shevchenko, K.V., V’yunova, T.V., Rybalkina, E.Yu., Andreyeva, L.A., Nagaev, I.Yu., Shevchenko, V.P., Bezuglov, V.V., Akimov, M.G., Ushakova, N.A., and Myasoedov, N.F., V S’yezd Farmakologov RossiiNauchnyie osnovy poiska i sozdaniya novykh lekarstv” (V Congress of Pharmacologists of Russia “Scientific Basis for the Search and Creation of New Drugs”), Yaroslavl, May 14–18, 2018, p. 270.Google Scholar
  18. 18.
    Seredenin, S.B., Kozlovskaya, M.M., Blednov, Yu.A., Semenova, T.P., Kozlovskiy, I.I., Chabak-Gorbach, R., Nezavibat’ko, V.N., and Myasoedov N.F., Pavlov Zhurn. Vyssh. Nervn. Deyat., 1998, vol. 48, no. 1, pp. 153–160.Google Scholar
  19. 19.
    Kost, N.V., Sokolov, O.Yu., Gabayeva, M.V., Grivennikov, I.A., Andreeva, L.A., Myasoedov N.F., and Zozulya, A.A., Bioorgan. Khim., 2001, vol. 27, no. 3, pp. 180–183.Google Scholar
  20. 20.
    Zozulya, A.A., Meshavkin, V.K., Toropov, A.V., Gurevich, K.G., and Kost, N.V., Byul. Eksper. Biol. Med., 1999, vol., 127, no. 2, pp. 211–214.Google Scholar
  21. 21.
    Sokolov, O.Yu., Meshavkin, V.K., Kost, N.V., and Zozulya, A.A., Byul. Eksper. Biol. Med., 2002, vol. 133, no. 2, pp. 158–161.Google Scholar
  22. 22.
    Glazova, N.Yu., Levitskaya, N.G., Andreeva, L.A., Kamenskii, A.A., and Myasoedov, N.F., Dokl. Akad. Nauk., 1999, vol. 367, no. 1, pp. 137–140.Google Scholar
  23. 23.
    Shevchenko, K.V., Andreeva, L.A., Shevchenko, V.P., and Myasoedov, N.F., Khim.-Farm. Zhurn., 2016, vol. 52, no. 8, pp. 7–11.Google Scholar
  24. 24.
    Shevchenko, V.P., Shevchenko, K.V., Nagaev, I.Yu., Andreeva, L.A., and Myasoedov, N.F., V S’yezd Farmakologov Rossii “Nauchnyie osnovy poiska i sozdaniya novykh lekarstv” (V Congress of Pharmacologists of Russia “Scientific Basis for the Search and Creation of New Drugs”), Yaroslavl, May 14−18, 2018, p. 270.Google Scholar
  25. 25.
    Obergan, T.Yu., Shubina, T.A., Grigor’yeva, M.E., Lyapina, L.A., Myasoedov, N.F., and Andreeva, L.A., Sovremennyie Problemy Nauki i Obrazovaniya, 2017, no. 3, pp. 23–30.Google Scholar
  26. 26.
    Lyapina, L.A., Myasoedov, N.F., Andreeva, L.A., Ul’yanov, A.M., Obergan T.Yu., Shubina, T.A., and Pastorova, V.E., Izv. Rus. Akad. Nauk, Biol. Ser., 2010, no. 3, pp. 375–379.Google Scholar
  27. 27.
    Andreeva, L.A., Lyapina, L.A., Myasoedov, N.F., Nemerskiy, A.V., Pinelis, V.G., and Shram, S.I., Rus. Patent no. 2480234 (27.04.2013), Byul. Izobret., 2013, no. 12.Google Scholar
  28. 28.
    Lyapina, L.A., Andreeva, L.A., Ul’yanov, A.M., Obergan, T.Yu., Shubina, T.A., Pastorova, V.E., and Myasoedov, N.F., Rus. Patent no. 2378005 (10.01.2010), Byul. Izobret., 2010, no. 1.Google Scholar
  29. 29.
    Ashmarin, I.P., Baglikova, K.E., Edeyeva, S.E., Zolotarev, Yu.A., Kozik, V.S., Dadayan, A.K., Dorokhova, E.M., Alfeeva L.Yu., Andreeva, L.A., Kopylova, G.N., Pavlov, T.S., Vas’kovskiy, B.V., Meshavkin, V.K., Sokolov, O.Yu., Kost, N.V., Zozulya, A.A., Samonina, G.E., and Myasoedov, N.F., Bioorgan. Khim., 2008, vol. 34, no. 4, pp. 464–470.Google Scholar
  30. 30.
    Ul’yanov, A.M., Lyapina, L.A., and Shubina, T.A., Vopr. Biol. Med. Farm. Khim., 2005, no. 4, pp. 19−21.Google Scholar
  31. 31.
    V’yunova, T.V., Shevchenko, K.V., Andreeva, L.A., Shevchenko, V.P., Radilov, A.S., Dulov, S.A., Petunov, S.G., and Myasoedov, N.F., Khim.-Farm. Zhurn., 2017, vol. 51, no. 5, pp. 9–12.Google Scholar
  32. 32.
    Shevchenko, K.V., V’yunova, T.V., Nagaev, I.Yu., Andreeva, L.A., and Myasoedov, N.F., Bioorgan. Khim., 2013, vol. 39, no. 3, pp. 320–325.Google Scholar
  33. 33.
    Shevchenko, K.V., V’yunova, T.V., Andreeva, L.A., Nagaev, I.Yu., Shevchenko, V.P., and Myasoedov, N.F., Khim.-Farm. Zhurn., 2015, vol. 49, no. 2, pp. 12–17.Google Scholar
  34. 34.
    V’yunova, T.V., Andreeva, L.A., Shevchenko, K.V., Shevchenko, V.P., Bobrov, M.Yu., Bezuglov, V.V., and Myasoedov, N.F., Dokl. Akad. Nauk, 2008, vol. 419, no. 1, pp. 136–137.Google Scholar
  35. 35.
    Shevchenko, K.V., Dulov, S.A., Andreeva, L.A., Nagaev, I.Yu., Shevchenko, V.P., Radilov, A.S., and Myasoedov, N.F., Bioorgan. Khim., 2016, vol. 42, no. 2, pp. 171–181.Google Scholar
  36. 36.
    Shevchenko, K.V., Radilov, A.S., Andreeva, L.A., Nagaev, I.Yu., Shevchenko, V.P., Rembovskiy, V.R., and Myasoedov, N.F., VII Rossiiskyi Simpozium “Belki i peptidy” (VII Russian Symposium “Proteins and Peptides”), Novosibirsk, July 12–17, 2015, p. 431.Google Scholar
  37. 37.
    Shevchenko, V.P., Nagaev, I.Yu., and Myasoe-dov, N.F., Mechennyye tritiyem lipofil’nyye soedineniya (Tritium-Labeled Lipophilic Compounds), Moscow: Nauka, 2003.Google Scholar
  38. 38.
    Shevchenko, V.P., Radilov, A.S., Nagaev, I.Yu., Shevchenko, K.V., Rembovskii, V.R., and Myasoe-dov, N.F., Radiokhimiya, 2015, vol. 57, no. 5, pp. 463–465.Google Scholar
  39. 39.
    Shevchenko, V.P., Nagaev, I,Yu., Shevchenko, K.V., and Myasoedov, N.F., Radiokhimiya, 2013, vol. 55, no. 3, pp. 284–288.Google Scholar
  40. 40.
    Shevchenko, V.P., Nagaev, I,Yu., Andreeva, L.A., and Myasoedov, N.F., Dokl. Akad. Nauk, 2017, vol. 473, no. 5, pp. 564–567.Google Scholar
  41. 41.
    Shevchenko, V.P., Nagaev, I.Yu., Petunov, S.G., Shevchenko, K.V., and Myasoedov, N.F., Dokl. Akad. Nauk, 2015, vol. 464, no. 5, pp. 562–567.Google Scholar
  42. 42.
    Shevchenko, K.V., V’yunova, T.V., Andreeva, L.A., Shevchenko, V.P., and Myasoedov, N.F., VI Rossiiskyi Simpozium “Belki i peptidy”(VI Russian Symposium “Proteins and Peptides”), Ufa, June 11–15, 2013, p. 173.Google Scholar
  43. 43.
    Shevchenko, K.V., V’yunova, T.V., Andreeva, L.A., Nagaev, I.Yu., Shevchenko, V.P., and Myasoedov, N.F., Byul. Eksper. Biol. Med., 2014, vol. 158, no. 7, pp. 43–48.Google Scholar
  44. 44.
    Shevchenko, K.V., V’yunova, T.V., Andreeva, L.A., Nagaev, I.Yu., Shevchenko, V.P., and Myasoedov, N.F., Dokl. Akad. Nauk, 2014, vol. 456, no. 5, pp. 613–617.Google Scholar
  45. 45.
    Davtyan, M.A. and Airapetyan, N.N., Biol. Zhurn. Armenii, 1998, vol. 51, nos. 1–2, pp. 3–6.Google Scholar
  46. 46.
    Blanchard, M., Green, D.E., Nocito, V., and Ratner, S., J. Biol. Chem., 1944, vol. 155, no. 2, pp. 421–440.Google Scholar
  47. 47.
    Privalova, A.M., Gulyaeva, N.V., and Bukreeva, T.V., Neurochem. J., 2012, vol. 29, no. 2, pp. 93–105.Google Scholar
  48. 48.
    Nagaev, I.Yu., Shevchenko, V.P., Shevchenko, K.V., Andreeva, L.A., Shram, S.I., and Myasoedov, N.F., V S’yezd farmakologov Rossii “Nauchnyie osnovy poiska i sozdaniya novykh lekarstv” (V Congress of Pharmacologists of Russia “Scientific Basis for the Search and Creation of New Drugs”), Yaroslavl, May 14–18, 2018, p. 167.Google Scholar
  49. 49.
    Shevchenko, K.V., Nagaev, I.Yu., Babakov, V.N., Andreeva, L.A., Shevchenko, V.P., Radilov, A.S., and Myasoedov, N.F., Dokl. Akad. Nauk, 2015, vol. 464, no. 3, pp. 373–376.Google Scholar
  50. 50.
    Shevchenko, K.V., Andreeva, L.A., Nagaev, I.Yu., Shevchenko, V.P., and Myasoedov, N.F., II Nauchnaya konferentsiya “Fiziologicheskaya aktivnost’ regulyatornykh peptidov” posvyashchennaya 90-letiyu akademika RAMN I.P. Ashmarina (The Second Scientific Conference “Physiological Activity of Regulatory Peptides” Dedicated to 90th Birthday of Academician of RAMS I.P. Ashmarin), Moscow, September 18, 2015, p. 45.Google Scholar
  51. 51.
    Shevchenko, K.V., Nagaev, I.Yu., Shevchenko, V.P., Andreeva, L.A., Shram, S.I., and Myasoedov, N.F., Dokl. Akad. Nauk, 2017, vol. 473, no. 3, pp. 742–745.Google Scholar
  52. 52.
    Shevchenko, K.V., V’yunova, T.V., Radilov, A.S., Andreeva, L.A., Nagaev, I.Yu., Shevchenko, V.P., Rembovskii, V.P., and Myasoedov, N.F., VII Rossiiskyi Simpozium “Belki i peptidy” (VII Russian Symposium “Proteins and Peptides”), Novosibirsk, July 12–17, 2015, p. 430.Google Scholar
  53. 53.
    Shevchenko, K.V., V’yunova, T.V., Radilov, A.S., Andreeva, L.A., Nagaev, I.Yu., Shevchenko, V.P, Rembovskii, V.P., and Myasoedov, N.F., Dokl. Akad. Nauk, 2015, vol. 465, no. 6, pp. 749–752.Google Scholar
  54. 54.
    Furubayashi, T., Kamaguchi, A., Kawaharada, K., Masaoka, Y., Kataoka, M., Yamashita, S., Higashi, Y., and Sakane, T., Biol. Pharm. Bull., 2007, vol. 30, no. 5, pp. 1007–1010.CrossRefGoogle Scholar
  55. 55.
    Privalova, A.M., Gulyaeva, N.V., and Bukreeva, T.V., Neurochem. J., 2012, vol. 29, no. 2, pp. 93–105.Google Scholar
  56. 56.
    Walter, R., Simmons, W.H., and Yoshimoto, T., Mol. Cell Biochem., 1980, vol. 30, no. 2, pp. 111–127.CrossRefGoogle Scholar
  57. 57.
    McDonald, J.K. and Barett, A.J., Mammalian Proteases: A Glossary and Bibliography Vol. 2. Exopeptidases, London: Academic Press, 1986.Google Scholar
  58. 58.
    Mentlein, R., FEBS Lett., 1988, vol. 234, no. 2, pp. 251–256.CrossRefGoogle Scholar
  59. 59.
    Walker, J.R., Altman, R.K., Warren, J.W., and Altman, E., J. Pept. Res., 2003, vol. 62, no. 5, pp. 214–226.CrossRefGoogle Scholar
  60. 60.
    Hooper, N.M., Htyszko, J., and Turner, A.J., Biochem. J., 1990, vol. 267, no. 2, pp. 509–515.CrossRefGoogle Scholar
  61. 61.
    Fleminger, G. and Yaron, A., Biochim. Biophys. Acta., 1984, vol. 789, no. 3, pp. 245–256.CrossRefGoogle Scholar
  62. 62.
    Lin, L.N. and Brandts, J.F., Biochemistry, 1979, vol. 18, no. 23, pp. 5037–5042.CrossRefGoogle Scholar
  63. 63.
    Yaron, A. and Naider, F., Crit. Rev. Biochem. Mol. Biol., 1993, vol. 28, no. 1, pp. 31–81.CrossRefGoogle Scholar
  64. 64.
    Lin, L.N. and Brandts, J.F., Biochemistry, 1979, vol. 18, no. 1, pp. 43–47.CrossRefGoogle Scholar
  65. 65.
    King, G.F. and Kuchel, P.W., Biochem. J., 1985, vol. 220, no. 2, pp. 553–560.CrossRefGoogle Scholar
  66. 66.
    Kenny, A.J., Booth, A.G., George, S.G., Ingram, J., Kershaw, D., Wood, E.J., and Young, A.R., Biochem. J., 1976, vol. 157, no. 1, pp. 169–182.CrossRefGoogle Scholar
  67. 67.
    Heins, J., Welker, P., Schonlein, C., Born, I., Hartrodt, B., Neubert, K., Tsuru, D., and Barth, A., Biochim. Biophys. Acta, 1988, vol. 954, no. 2, pp. 161–169.CrossRefGoogle Scholar
  68. 68.
    Morita, A., Chung, Y.C., Freeman, H.J., Erickson, R.H., Sleisinger, M.H., and Kim, Y.S., J. Clin. Invest., 1983, vol. 72, no. 2, pp. 610–616.CrossRefGoogle Scholar
  69. 69.
    Mentlein, R. and Struckhoff, G., J. Neurochem., 1989, vol. 52, no. 4, pp. 1284–1293.CrossRefGoogle Scholar
  70. 70.
    Semenova, A.I., Prakticheskaya Onkologiya, 2009, vol. 10, no. 3, pp. 168–176.Google Scholar
  71. 71.
    Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L., Pharmacol. Rev., 2004, vol. 56, no. 2, pp. 185–229.CrossRefGoogle Scholar
  72. 72.
    Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., Janssens, S., Crijns, H.J., and Moens, A.L., J. Mol. Cell. Cardiol., 2012, vol. 52, no. 6, pp. 1213–1225.CrossRefGoogle Scholar
  73. 73.
    Huang, S., Fang, R., Xu, J., Qiu, S., Zhang, H., Du, J., and Cai, S., J. Drug Target., 2011, vol. 19, no. 7, pp. 487–496.CrossRefGoogle Scholar
  74. 74.
    Deng, Y., Gao, P., Guo, C., Wu, L., Xu, J., Chen, H., and Cai, Sh., Med. Chem., 2013, vol. 3, no. 2, pp. 199–205.CrossRefGoogle Scholar
  75. 75.
    el-Beltagi, H.M., Martens, A.C., Lelieveld, P., Haroun, E.A., and Hagenbeek, A., Cancer Res., 1993, vol. 53, no. 13, pp. 3008–3014.Google Scholar
  76. 76.
    LoRusso, P.M., Demchik, L., Foster, B., Knight, J., Bissery, M.C., Polin, L.M., Leopold, W.R., 3rd, and Corbett, T.H., Invest. New Drugs, 1996, vol. 14, no. 4, pp. 349–356.CrossRefGoogle Scholar
  77. 77.
    Seelig, M.H. and Berger, M.R., Eur. J. Cancer, 1996, vol. 32A, no. 11, pp. 1968–1976.CrossRefGoogle Scholar
  78. 78.
    Thomas, M., Clarhaut, J., Tranoy-Opalinski, I., Gesson, J.P., Roche, J., and Papot, S., Bioorg. Med. Chem., 2008, vol. 16, no. 17, pp. 8109–8116.CrossRefGoogle Scholar
  79. 79.
    Pires, A., Fortuna, A., Alves, G., and Falcao, A., J. Pharm. Pharmaceut. Sci., 2009, vol. 12, no. 3, pp. 288–311.CrossRefGoogle Scholar
  80. 80.
    Costantino, H.R., Illum, L., Brandt, G., Johnson, P.H., and Quay, S.C., Int. J. Pharm., 2007, vol. 337, nos. 1–2, pp. 1–24.CrossRefGoogle Scholar
  81. 81.
    Sarkar, M.A., Pharm. Res., 1992, vol. 9, no. 1, pp. 1−9.CrossRefGoogle Scholar
  82. 82.
    Wong, Y.C. and Zuo, Z., Pharm. Res., 2010, vol. 27, no. 7, pp. 1208–1223.CrossRefGoogle Scholar
  83. 83.
    Ashmarin, I.P., Kamenskii, A.A., Lyapina, L.A., Myasoedov, N.F., and Samonina, G.E., Vopr. Biol. Med. Farm. Khimii, 2002, no. 1, pp. 24–27.Google Scholar
  84. 84.
    Haddox, J.L., Pfister, R.R., Muccio, D.D., Villain, M., Sommers, C.I., Chaddha, M., Anantharamaiah, G., Brouillette, W.J., and De Lucas, L.J., Invest. Ophthalmol. Vis. Sci., 1999, vol. 40, no. 10, pp. 2427–2429.Google Scholar
  85. 85.
    Badmaeva, K.E., Samonina, G.E., Vaskovskii, B.V., and Platonova, R.D., Vestnik Moskovskogo Universiteta, Ser. 16, Biologiya, 2004, no. 4, pp. 7–9.Google Scholar
  86. 86.
    Bakaeva, Z.V., Samonina, G.E., Andreeva, L.A., Zolotarev, Yu.A., Kozik, V.A., Ashmarin, I.P., and Myasoedov, N.F., Eksper. Klin. Farmakol., 2004, vol. 67, pp. 72–75.Google Scholar
  87. 87.
    Vaskovskii, B.V., Zolotarev, Yu.A., Zhuikova, S.E., Samonina, G.E., Ashmarin, I.P., Myasoedov, N.F., Lyapina, L.A., Pastorova, V.E., and Bakaeva, Z.V., Vopr. Biol. Med. Farm. Khimii, 2003, no. 3, pp. 41–45.Google Scholar
  88. 88.
    Zolotarev, Yu.A., Zhuikova, S.E., Ashmarin, I.P., Myasoedov, N.F., Vaskovskii, B.V., and Samo-nina, G.E., Byul. Eksper. Biol. Med., 2003, vol. 135, no. 4, pp. 423–426.Google Scholar
  89. 89.
    Abramova, M.A., Samonina, G.E., and Ashmarin, I.P., Neurochem. J., 1996, vol. 13, no. 3, pp. 209–214.Google Scholar
  90. 90.
    Ashmarin, I.P., Samonina, G.E., Zheleznik, N.Ya., and Bakaeva, Z.V., Dokl. Akad. Nauk, 1999, vol. 368, no. 5, pp. 709–710.Google Scholar
  91. 91.
    Kopylova, G.N., Badmaeva, S.E., Levitskaya, N.G., Samonina, G.E., Umarova, B.A., and Guseva, A.A., Byul. Eksper. Biol. Med., 2004, vol. 137, vol. 7, pp. 9–12.Google Scholar
  92. 92.
    Samonina, G.E., Lyapina, L.A., Kopylova, G.N., Pastorova, V.E., Bakaeva, Z.V., Jeliaznik, N., Zuykova, S.E., and Ashmarin, I.P., Pathophysiology, 2000, vol. 7, no. 1, pp. 69–73.CrossRefGoogle Scholar
  93. 93.
    Samonina, G.E., Ashmarin, I.P., and Lyapina, L.A., Pathophysiology, 2002, vol. 8, no. 4, pp. 229–234.CrossRefGoogle Scholar
  94. 94.
    Zhuikova, S.E., Badmaeva, K.E., Samonina, G.E., and Plesskaya, L.G., Eksper. Klin. Gastroenterol., 2003, no. 4, pp. 88–92.Google Scholar
  95. 95.
    Charlton, S.T., Whetstone, J., Fayinka, S.T., Read, K.D., Illum, L., and Davis, S.S., Pharm. Res., 2008, vol. 25, no. 7, pp. 1531–1543.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2019

Authors and Affiliations

  • K. V. Shevchenko
    • 1
    Email author
  • I. Yu. Nagaev
    • 1
  • L. A. Andreeva
    • 1
  • V. P. Shevchenko
    • 1
  • N. F. Myasoedov
    • 1
  1. 1.Institute of Molecular Genetics of the Russian Academy of SciencesMoscowRussia

Personalised recommendations